ArticleMethods in molecular biology (Clifton, N.J.)2024
Split-Protein Therapeutic Platforms: Identifying Binder Pairs.
Article in Methods in molecular biology (Clifton, N.J.), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Therapeutic proteins, including enzymes, interferons, interleukins, and growth factors, are emerging as important modalities to treat many diseases that elude management by small molecule drugs. One challenge of protein treatment is the propensity for off-target or systemic activity. A promising approach to overcome such toxicity is to create conditionally active constructs by splitting the therapeutic protein into two, or more, inactive fragments and by fusing these fragments to binders (e.g., antibodies) that target distinct epitopes on a cell surface. When these antibodies bind to their respective targets, the protein fragments are brought into proximity and then reconstitute into the active form of the therapeutic protein. In this chapter, we describe approaches to determine antibody pairs that enable the reconstitution of the active protein. General computational and empirical methods are provided to facilitate the identification of pairs starting only from protein sequence data.
Indexed as
Identifiers
37775658What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.